Drugs / Imeroprubart
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07032662 | Mar 2025 → Aug 2028 expected | polyneuropathy, inflammatory demyelinating, chronic | Immunovant Sciences GmbH | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imeroprubart | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07032662 ↗ |
| Modality | Monoclonal antibody | — CHEMBL6068254 ↗ |
| Route | Subcutaneous | “Dose 1 subcutaneous (SC) once weekly (QW) for 24 weeks (Period 1) and 52 weeks (Period 2)” NCT07032662 ↗ |